Ocugen to Report Q4 and Full Year 2025 Results on March 4, 2026
Ocugen will host a conference call on March 4, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and provide a business update, with a pre-market earnings announcement the same day.
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day.
Attendees are invited to participate on the call using dial-in numbers (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers, with Conference ID 3029428. The webcast will be available on the events section of the Ocugen investor site. A replay of the call and archived webcast will be available on the Ocugen investor site.
The company experienced a transformative year in 2025, marked by significant progress in its modifier gene therapy programs. Ocugen secured important licensing and financing agreements that bolstered its financial standing. Strategic appointments were made to the leadership team, positioning Ocugen for future growth.
The company is preparing for upcoming strategic events, including the submission of its first Biologics License Application (BLA) among three planned filings.
Ocugen's modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen's modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. The company has programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration.
The company's financial metrics as of 2025 showed revenue of $5.37 million, with no growth over the past three years. The company had a market capitalization of $608.82 million and a current ratio of 1.85. The debt-to-equity ratio stood at 9.33.